So . . . congress recently passed $1,000,000,000 to address the opioid crisis. Much of that money is expected to be spent on medication assisted treatment.
Buprenorphine has been the most frequently touted form of medication assisted treatment. I’ve reviewed the research here and found that it does not live up to the hype.
A new study of buprenorphine was just published. It looks at prescription opioid use during and after buprenorphine treatment.
For their study, Alexander and his colleagues examined pharmacy claims for more than 38,000 new buprenorphine users who filled prescriptions between 2006 and 2013 in 11 states. They looked at non-buprenorphine opioid prescriptions before, during, and after each patient’s first course of buprenorphine treatment, which typically lasted between one to six months. Even though there are no universally agreed-upon guidelines regarding the optimal length of treatment, most people discontinued buprenorphine within three months.
They found that 43 percent of patients who received buprenorphine filled an opioid prescription during treatment and 67 percent filled an opioid prescription during the 12 months following buprenorphine treatment. Most patients continued to receive similar amounts of opioids before and after buprenorphine treatment.
They described buprenorphine’s impact and retention like this:
Buprenorphine therapy was associated with modest declines in most measures of opioid use following the first treatment episode; however, only 33% of patients continued to fill prescriptions for buprenorphine after 3 months.
Families and people with opioid problems are NOT looking for modest declines in use and a 67% drop out rate within 3 months.